Multiple Sclerosis

Epidemiology of Multiple Sclerosis

MS is the most common chronic autoimmune disease affecting the CNS, with a higher prevalence in developed countries. Globally, around 2.8 million people are affected as of 2020, with a prevalence of about 30-80 per 100,000 people. The incidence is approximately 2-10 new cases per 100,000 individuals annually. The typical age of onset varies, with relapsing-remitting MS (RRMS) starting around 25-29 years old and primary progressive MS (PPMS) around 40 years old.

The female-to-male ratio is approximately 1.4 to 2.3:1, and recent studies suggest it's increasing to 3:1 due to a higher incidence in females, possibly related to hormonal and genetic factors. MS patients have a higher risk of other autoimmune diseases like type 1 diabetes and thyroid disease, indicating an abnormal immune system, which may be due to shared genetic or environmental risk factors. The prevalence of MS is higher in northern regions away from the equator, such as North America and Europe (about 1 in 1000), while lower in areas closer to the equator. In the UK, the prevalence is about 1 in 500, with variations even within the UK (lower in Northern Ireland), likely due to a combination of genetic and environmental influences.

Risk Factors

There are no specific genes that guarantee MS, but genetic predisposition is important. Human genome studies have identified around 2,200 polymorphisms that increase the risk, primarily related to immune function. Studies have focused on HLA and TRPV1, with vitamin D response elements located in the promoter regions of HLA-DRB1. However, the effect varies across ethnic groups; for example, in the Sardinian population, HLA-B1 had no effect, while polymorphisms of B-cell activating factors regulatory elements were more important. This highlights the complexity of genetic contributions and the importance of considering population-specific genetic architectures.

MS is considered an epigenetic disease, meaning it's not purely genetic. Epigenetic modifications, such as DNA methylation and histone modification, can alter gene expression in response to environmental factors. Among homozygous twins, the correlation is only about 20-30%. If one sibling has MS, the risk for the other is only 3-5%, and for a first-degree relative, the risk is about 2.5%. This suggests that environmental factors influenced by genetics increase the risk, and epigenetic mechanisms may mediate these gene-environment interactions.

Environmental Factors

Viral infections, particularly Epstein-Barr virus (EBV), significantly increase the risk of MS. Having EBV can increase the risk by 30-fold. Recent studies indicate that EBV nuclear antigen one has a cross-link that mimics glial cell adhesion molecules, suggesting that EBV infections increase the risk for autoimmune diseases by triggering molecular mimicry. Sunlight and vitamin D are also important, with people closer to the equator having a reduced prevalence of MS, potentially due to UV light or high vitamin D levels. Vitamin D modulates immune responses and impacts the expression of genes involved in MS pathogenesis. Tobacco smoking increases the risk of MS and disease progression, especially during childhood and adolescence, likely due to its pro-inflammatory effects and impacts on immune regulation. Obesity also increases the risk, potentially by promoting chronic inflammation and altering immune responses. There is no association between vaccination and MS; studies have debunked any link between vaccines and the development of MS, emphasizing that vaccinations are safe and do not increase MS risk.

Pathophysiology of MS

MS is an autoimmune disease where the blood-brain barrier breaks down, allowing T cells and B cells to migrate into the brain and attack the myelin sheath in the CNS. This immune cell infiltration is mediated by chemokines and adhesion molecules. Demyelination disrupts nerve signal transmissions, leading to axonal damage and neuronal loss over time. Chronic inflammation and demyelination result in the formation of lesions and plaques in the brain and spinal cord. MRI findings show lesions, typically seen as fluffy ovoid shapes or plaques, which are hallmarks of the disease.

Prodromal Symptoms

Recent data from the last four years indicate prodromal symptoms can occur 5-10 years before diagnosis. These early symptoms are often subtle and non-specific, making early diagnosis challenging. Patients tend to visit doctors for non-specific symptoms, such as reduced cognitive performance, mood disorders, and fatigue. Conditions include radiologically isolated syndrome (RIS), where patients are asymptomatic but have MRI findings suggestive of MS, and clinically isolated syndrome (CIS), where patients have a first clinical event with multiple lesions on MRI. RIS patients have a higher risk of converting to clinically definite MS over time.

Phenotypes of MS

  1. Relapsing-Remitting MS (RRMS): Accounts for about 85% of cases. Patients experience relapses followed by recovery back to baseline. Relapses involve acute worsening of neurological symptoms. Over time, it can progress into secondary progressive MS. The transition to SPMS is often marked by a gradual accumulation of disability, independent of relapses.

  2. Secondary Progressive MS (SPMS): Disability accumulates, with occasional relapses. SPMS typically evolves from RRMS, with a progressive worsening of neurological function. The rate of progression varies among individuals.

  3. Primary Progressive MS (PPMS): Accounts for 10-15% of cases. Gradual deterioration in neurological functions without clear relapses or remissions. Onset tends to be later, around 40 years old. PPMS is characterized by a steady accumulation of disability from the onset of the disease.

  4. Progressive-Relapsing MS (PRMS): Patients progress like primary progressive MS but may have relapses in between. PRMS is a less common form of MS, characterized by progression from the onset with distinct relapses.

Clinical Features

There are no particular clinical findings unique to MS, but certain features are highly suggestive, such as relapses and remissions. The presentation can be highly variable depending on the location and extent of demyelination. Typical age range is between 15 to 50 years old. Common symptoms include:

  • Neuralgia, particularly trigeminal neuralgia.

  • Fatigue, which is often debilitating and impacts daily functioning.

  • Optic neuritis (often the first sign): Causes eye pain and vision loss.

  • Lhermitte's sign (electrical shock-like sensations along the spine with neck flexion).

  • Internuclear ophthalmoplegia (INO): Impaired horizontal eye movement.

  • Heat sensitivity (Uhthoff's phenomenon): Symptoms worsen with increased body temperature.

Neurological symptoms depend on the affected part of the CNS:

  • Motor symptoms: Weakness, increased muscle tone (spasticity), paralysis.

  • Sensory symptoms: Numbness, tingling, pain, burning sensations.

  • Visual symptoms: Optic neuritis, color desaturation, eye pain, double vision, blurred vision.

  • Cognitive symptoms: Memory loss, difficulty concentrating, impaired executive function.

  • Other symptoms: Fatigue, bowel and bladder control dysfunction, depression, sexual dysfunction.

Diagnosis of MS

An attack is defined as neurological problems lasting more than 24 hours in the absence of fever or infections. The symptoms must be objective and not due to other causes. Objective findings are required from neurologic exams and imaging (MRI or CT scans). Additional evidence can come from optical coherence tomography (OCT) and neurophysiology (visual evoked potentials).

The principal diagnostic criteria are dissemination in space and dissemination in time, which are essential for confirming the diagnosis of MS.

  • Dissemination in Space: One or more hyperintense T2 lesions on MRI scans in at least two of the typical locations (periventricular, cortical, spinal cord). These lesions represent areas of demyelination and inflammation.

  • Dissemination in Time: Another clinical attack or simultaneous findings on imaging (one older lesion and one enhancing lesion). Enhancing lesions indicate active lesions with blood-brain barrier breakdown. This demonstrates that lesions have occurred at different points in time.

Updated McDonald criteria in 2017 include CSF-specific oligoclonal bands, which can substitute for dissemination in time, allowing for earlier diagnosis in some cases. The presence of oligoclonal bands in the CSF indicates intrathecal synthesis of immunoglobulin, a sign of chronic inflammation in the CNS.

Diagnostic Examples

  1. Two clinical attacks and two lesions on imaging: Diagnosis established.

  2. Two clinical attacks and one lesion on imaging: Wait for further evidence of dissemination in space.

  3. One clinical attack and two lesions on MRI: Wait to satisfy dissemination criteria. Additional MRI scans may be needed to demonstrate dissemination in time.

Typical MRI findings include white matter changes in periventricular, cortical, and spinal cord areas. Lesions appear as ovoid shapes. Dorsal fingers are a unique finding. Gadolinium-enhancing lesions suggest active lesions. These findings help differentiate MS from other neurological conditions.

CSF Findings

Oligoclonal bands indicate antibody production in the CNS. While 90-95% of patients with definitive MS have positive oligoclonal bands, early phases may show negative results. About 5% of non-MS patients may have false positives. Copper-free light chain is a new development proposed in 2024, identifying MS with sensitivity and specificity. This biomarker shows promise in improving diagnostic accuracy.

The McDonald diagnostic criteria are constantly updated to improve specificity and accuracy, allowing for earlier diagnosis. The criteria are revised based on new research and clinical evidence. New imaging factors include paramagnetic rim lesions indicating chronic lesions surrounded by residual microglia or macrophages. These rim lesions are associated with more severe disease and long-term disability.

Differential Diagnosis

The differential diagnosis is extensive, and it is important to differentiate them. Conditions such as neuromyelitis optica spectrum disorder (NMOSD), acute disseminated encephalomyelitis (ADEM), and vasculitis should be considered. For example, in pediatric patients, you need to consider conditions like ADEM and Lyme disease, as treatments differ. Accurate diagnosis is crucial to ensure appropriate treatment strategies are implemented.

Treatment of MS

Treatment is twofold:

  1. Acute phase (relapses): High doses of steroids (e.g., methylprednisolone) to hasten recovery, but they have no long-term effects and have side effects like blood pressure and sugar control problems. Steroids reduce inflammation in the CNS. Used for significant clinical problems like vision loss or weakness. Plasma exchange or intravenous immunoglobulin (IVIG) may be considered in severe relapses unresponsive to steroids.

  2. Long-term management: Disease-modifying treatments (DMTs) to reduce relapses and slow disease progression. These modulate the immune system to prevent it from migrating into the brain. DMT selection depends on disease activity and patient preference. Factors include efficacy, route of administration, and potential side effects. Family planning is crucial since some treatments are contraindicated in pregnant women. High-efficacy treatments are B-cell depletion agents and immunosuppressants. These treatments have a greater impact on reducing disease activity but also carry higher risks. Low-efficacy treatments include interferon beta. These treatments have a more modest effect on disease activity and are generally better tolerated.

Stem cell transplants involve wiping out the peripheral immune system and reinfusing the patient's own stem cells to suppress the bad ones. This treatment is not 100% effective though can lead to long-term remission. Hematopoietic stem cell transplantation (HSCT) is reserved for aggressive cases of MS that have not responded to other treatments. The procedure aims to reset the immune system and prevent further damage to the CNS.

Symptomatic Management

  • Spasticity: Manage with medications like gabapentin and pregabalin. Baclofen and tizanidine are also commonly used.

  • Neurogenic pain: Gabapentin and pregabalin are preferred. Other options include tricyclic antidepressants and selective serotonin reuptake inhibitors (SSRIs).

  • Nutrition and vitamin D: Supplementation is beneficial (many in the UK are vitamin D deficient). A balanced diet and regular exercise are also important.

  • Lifestyle modifications: Manage fatigue and avoid overexertion. Pacing activities and prioritizing rest can help reduce fatigue.

  • Physiotherapy and gait management: Functional electrical stimulation for foot drop. Exercise programs tailored to individual needs can improve mobility and strength.

  • Occupational therapy, cognitive rehabilitation, and speech therapy: Important for patient care. These therapies improve the quality of life and address specific deficits.

Future Directions

Focus on re-myelination and neuroprotection. Research is ongoing. Remyelinating therapies aim to promote myelin repair and protect axons from further damage. Precision medicine and personalized treatment are the future, based on genetics and biomarkers. Treatment strategies will be tailored to individual patient characteristics and disease profiles. Biomarkers will help monitor relapses and progression. Neurofilament light chain (NFL) is a promising biomarker for assessing axonal damage. Artificial intelligence will play an increasing role in analyzing data and predicting disease courses and treatment outcomes. AI can assist in identifying patterns and predicting treatment responses.

Summary

MS is a complex autoimmune disease. Advances in diagnosis and treatment have improved outcomes. Earlier diagnosis and more effective treatments have led to better long-term outcomes for patients. Before DMTs, patients often became wheelchair-bound within ten years. Now, many can maintain functionality. Ongoing research holds promise for better therapies. Emerging therapies and innovative treatment approaches are continuously being investigated. MS management requires a multidisciplinary approach. A team of neurologists, nurses, therapists, and other healthcare professionals is essential for comprehensive care.

Potential Questions on the Topic

  • How many phenotypes of MS are there?

  • What is a unique MRI finding in MS (e.g., dorsal fingers)?

  • What do oligoclonal bands substitute for in the diagnostic criteria (dissemination in time)?

  • What does an increase in NFL (neurofilament light chain) indicate (axonal breakdown)?